EFTR (eEFFECTOR Therapeutics Inc.) Net earnings per share (EPS TTM)

Symbol and logo of brand eFFECTOR Therapeutics (EFTR)

eFFECTOR Therapeutics (EFTR) bridges the academic community of oncology researchers with a search for lung cancer treatments that remains independent of economic cycles. The rolling net income per share is fixed at -12.62, illustrating the issuer's current resilience. Further molecular development will accelerate by delegating clinical trials to external CRO networks, thereby minimizing operational risks.

EFTR (eFFECTOR Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 08/04/2024

Analytical breakdowns and data insights for company eEFFECTOR Therapeutics, Inc. (EFTR)

- current quotes and average value forecast:
Price Chart eFFECTOR Therapeutics|EFTR - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization eEFFECTOR Therapeutics, Inc.|EFTR - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share eEFFECTOR Therapeutics|EFTR - Total Stockholders' Equity|Market Value to Book Value Ratio effector.com|EFTR - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital eFFECTOR Therapeutics|EFTR - Long-Term Liabilities to Capital|Short-Term Debt to Capital eEFFECTOR Therapeutics Inc.|EFTR - Company Aggregate Indebtedness|Debts to Book Capitalization eEFFECTOR Therapeutics, Inc.|EFTR - Long-Term Liabilities|Company Short-Term Debts eEFFECTOR Therapeutics|Quick Ratio effector.com
- net income and valuation multiples indicators:
EFTR - Net Income|Future Profit eFFECTOR Therapeutics|EFTR - Market Price to Net Income Ratio|Future Price to Earnings eEFFECTOR Therapeutics|EFTR - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization eEFFECTOR Therapeutics, Inc.|EFTR - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months eEFFECTOR Therapeutics|EFTR - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months effector.com|EFTR - Net earnings per one share growth for the current year|Earnings growth forecast for next year eFFECTOR Therapeutics
Summary company analysis:eFFECTOR Therapeutics (EFTR)
Manufactured products of eEFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics (EFTR) specializes in developing selective translation inhibitors to combat oncological diseases. By analyzing the TTM earnings per share chart from GURU.Markets, one can assess the real value of the business. This metric excludes the impact of paper revaluations and share count volatility, capturing the net financial result. This allows for the separation of fundamental stability from market noise. Investor loyalty toward clinical trials confirms the long-term potential of the capital.

Key competitors

AVBP - Earnings per share for the last twelve months|LTRN (Lantern Pharma Inc.) - Earnings per share for the last 12 months|BIAF: Net earnings per share (EPS TTM)